EWG Elevate’s Regeneron Pharmaceuticals REGN Stock Holding History

EWG Elevate’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13	Closed	-$9.38K	–	605
2022 Q4	$9.38K	Buy	+13	New	+$9.59K	﹤0.01%	390

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

EWG Elevate's REGN Position: Q1 2023 in Review

EWG Elevate sold out of Regeneron Pharmaceuticals (REGN) in Q1 2023, closing a stake of 13 shares — an estimated $9.38K sold.

EWG Elevate first reported a position in REGN in Q4 2022 and held it in 1 quarter. The position peaked at $9.38K in Q4 2022. 1,192 funds tracked by Wall St. Rank hold REGN as of Q1 2023.

EWG Elevate reported no remaining Regeneron Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
EWG Elevate sold 13 Regeneron Pharmaceuticals shares in Q1 2023, an estimated $9.38K.
EWG Elevate first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 1 quarter.
EWG Elevate's Regeneron Pharmaceuticals position peaked at $9.38K in Q4 2022.
1,192 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2023.

Based on EWG Elevate's 13F filing for Q1 2023, filed 13 Apr 2023.